taurine has been researched along with Alcohol Drinking in 101 studies
Alcohol Drinking: Behaviors associated with the ingesting of ALCOHOLIC BEVERAGES, including social drinking.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Data were collected during an 8-week randomized controlled trial of acamprosate for individuals with co-occurring bipolar disorder and alcohol dependence (n = 30)." | 9.16 | Impact of depressive symptoms on future alcohol use in patients with co-occurring bipolar disorder and alcohol dependence: a prospective analysis in an 8-week randomized controlled trial of acamprosate. ( Brady, KT; Brown, DG; Chiuzan, C; DeSantis, SM; Prisciandaro, JJ; Tolliver, BK, 2012) |
| "The present study compared two putative pharmacotherapies for alcohol abuse and dependence, dehydroepiandrosterone (DHEA) and pregnanolone, with two Food and Drug Administration (FDA)-approved pharmacotherapies, naltrexone and acamprosate." | 7.81 | Comparison of dehydroepiandrosterone (DHEA) and pregnanolone with existing pharmacotherapies for alcohol abuse on ethanol- and food-maintained responding in male rats. ( Amato, RJ; Hulin, MW; Lawrence, MN; Weed, PF; Winsauer, PJ, 2015) |
| " Chronic administration of acamprosate reduced both alcohol and water drinking during SIP, but did not significantly affect regulatory drinking or non-drinking measures." | 5.33 | Schedule-induced alcohol drinking: non-selective effects of acamprosate and naltrexone. ( Escher, T; Mittleman, G, 2006) |
| "Data were collected during an 8-week randomized controlled trial of acamprosate for individuals with co-occurring bipolar disorder and alcohol dependence (n = 30)." | 5.16 | Impact of depressive symptoms on future alcohol use in patients with co-occurring bipolar disorder and alcohol dependence: a prospective analysis in an 8-week randomized controlled trial of acamprosate. ( Brady, KT; Brown, DG; Chiuzan, C; DeSantis, SM; Prisciandaro, JJ; Tolliver, BK, 2012) |
| "This article explores the mechanisms of action and the potential responder profile of acamprosate, a compound efficacious in relapse prevention of alcoholism." | 4.84 | Acamprosate: recent findings and future research directions. ( Kiefer, F; Littleton, J; Mann, K; Spanagel, R, 2008) |
| "The combination of acamprosate and escitalopram suppressed EtOH intake in both nonstressed and stressed mice; hence, this combination is potentially helpful for AUD individuals with or without comorbid depression to reduce alcohol use." | 3.83 | Combined Effects of Acamprosate and Escitalopram on Ethanol Consumption in Mice. ( Aguiar, FS; Choi, DS; Hinton, DJ; Ho, AM; Jia, YF; Karpyak, VM; Qiu, Y; Weinshilboum, RM, 2016) |
| "The present study compared two putative pharmacotherapies for alcohol abuse and dependence, dehydroepiandrosterone (DHEA) and pregnanolone, with two Food and Drug Administration (FDA)-approved pharmacotherapies, naltrexone and acamprosate." | 3.81 | Comparison of dehydroepiandrosterone (DHEA) and pregnanolone with existing pharmacotherapies for alcohol abuse on ethanol- and food-maintained responding in male rats. ( Amato, RJ; Hulin, MW; Lawrence, MN; Weed, PF; Winsauer, PJ, 2015) |
| "Treatment with acamprosate, a compound used for relapse prevention treatment of alcoholism, was recently shown to be associated with increased plasma concentration of beta-endorphin in rats selectively bred for high alcohol preference." | 3.73 | Effects of treatment with acamprosate on beta-endorphin plasma concentration in humans with high alcohol preference. ( Jahn, H; Kiefer, F; Nakovics, H; Otte, C; Wiedemann, K, 2006) |
| " For men, taurine level was found to be close to that in Mediterranean countries, where there is low mortality from cardiovascular diseases." | 3.70 | Epidemiological and nutritional research on prevention of cardiovascular disease in China. ( Li, YH; Liu, XQ, 2000) |
| "Acamprosate, which has been shown to down-regulate the glutamatergic system, may be particularly effective for relief drinkers." | 2.84 | Reward and relief dimensions of temptation to drink: construct validity and role in predicting differential benefit from acamprosate and naltrexone. ( Mann, K; Roos, CR; Witkiewitz, K, 2017) |
| "Acamprosate is a widely utilized, efficacious treatment for relapse prevention in alcohol dependent patients." | 2.74 | The effect of acamprosate on alcohol craving and correlation with hypothalamic pituitary adrenal (HPA) axis hormones and beta-endorphin. ( Franck, J; Hammarberg, A; Jayaram-Lindström, N; Nylander, I; Reid, MS; Zhou, Q, 2009) |
| " Physiological, subjective, and psychomotor measures were collected daily during each dosing cycle." | 2.71 | Alcohol effects during acamprosate treatment: a dose-response study in humans. ( Brasser, SM; Houtsmuller, EJ; McCaul, ME, 2004) |
| "Acamprosate proved to be a safe and effective aid in treating alcohol-dependent patients and in maintaining the abstinence of patients during 2 years." | 2.68 | Relapse prevention by acamprosate. Results from a placebo-controlled study on alcohol dependence. ( Mann, K; Sass, H; Soyka, M; Zieglgänsberger, W, 1996) |
| "Alcohol use disorders are common, but only a small minority of patients receive adequate treatment." | 2.52 | Recent Developments in Pharmacotherapy of Alcoholism. ( Lieb, M; Soyka, M, 2015) |
| "Naltrexone is effective to treat alcohol dependence (decreased length and frequency of drinking bouts), but its severe side effects, including withdrawal symptoms, are difficult to overcome." | 2.50 | Alcohol use disorders and current pharmacological therapies: the role of GABA(A) receptors. ( Liang, J; Olsen, RW, 2014) |
| "Acamprosate was shown only to support abstinence; it did not influence alcohol consumption after the first drink." | 2.44 | Acamprosate supports abstinence, naltrexone prevents excessive drinking: evidence from a meta-analysis with unreported outcomes. ( Lehert, P; Leucht, S; Rösner, S; Soyka, M, 2008) |
| "Acamprosate is a proven effective intervention in the treatment of alcohol dependence." | 2.43 | Predictors of acamprosate efficacy: results from a pooled analysis of seven European trials including 1485 alcohol-dependent patients. ( Geerlings, PJ; Koeter, MW; Lehert, P; van den Brink, W; Verheul, R, 2005) |
| "Acamprosate is an anti-craving drug used for the pharmacotherapy of alcohol use disorder (AUD)." | 1.72 | Genetic variants associated with acamprosate treatment response in alcohol use disorder patients: A multiple omics study. ( Biernacka, JM; Choi, DS; Frye, MA; Geske, JR; Ho, MF; Karpyak, VM; Li, H; Moon, I; Oesterle, TS; Seppala, MD; Skime, MK; Wei, L; Weinshilboum, RM; Zhang, C; Zhang, L, 2022) |
| "Taurine is an amino acid usually added to energy drinks." | 1.56 | Taurine enhances voluntary alcohol intake and promotes anxiolytic-like behaviors in rats. ( Almeida, RF; Bandiera, S; de Paula, LF; Gomez, R; Hansen, AW; Izolan, LDR; Nietiedt, NA; Pulcinelli, RR, 2020) |
| "Acamprosate was applied subchronically for 2 days during withdrawal before the final behavioral test." | 1.42 | Effects of acamprosate on attentional set-shifting and cellular function in the prefrontal cortex of chronic alcohol-exposed mice. ( Carrasco, A; Hu, W; Kroener, S; Morris, B, 2015) |
| "Comorbidity of alcohol abuse and dependence with bipolar disorders is high." | 1.38 | Commentary on the study: impact of depressive symptoms on future alcohol use in patients with co-occurring bipolar disorder and alcohol dependence: a prospective analysis in an 8-week randomized controlled trial of acamprosate (Prisciandaro et al.). ( Preuss, UW, 2012) |
| "Treatment with neramexane that shares part of the pharmacological effects of acamprosate on NMDA receptors, however, resulted in a nonselective reduction of lever responding." | 1.33 | The effects of acamprosate and neramexane on cue-induced reinstatement of ethanol-seeking behavior in rat. ( Bachteler, D; Ciccocioppo, R; Danysz, W; Economidou, D; Spanagel, R, 2005) |
| " Chronic administration of acamprosate reduced both alcohol and water drinking during SIP, but did not significantly affect regulatory drinking or non-drinking measures." | 1.33 | Schedule-induced alcohol drinking: non-selective effects of acamprosate and naltrexone. ( Escher, T; Mittleman, G, 2006) |
| " This selective increase in responding for ethanol was blocked by chronic administration of acamprosate." | 1.32 | Effects of naltrexone alone and in combination with acamprosate on the alcohol deprivation effect in rats. ( Heyser, CJ; Koob, GF; Moc, K, 2003) |
| "Acamprosate treatment decreased GECAT and increased Cease control rats, but increased GECAT and decreased CEase in PRF animals." | 1.32 | Acamprosate involvement in triacylglycerol hydrolysis and transacylation with cholesterol in chronically ethanol-drinking rats. ( Kaminska, E; Mikolajczak, P; Okulicz-Kozaryn, I; Piorunska-Mikolajczak, A; Piorunska-Stolzmann, M, 2004) |
| " Chronic administration of lower daily doses of acamprosate (100 and 200 mg/kg) blocked the increased ethanol consumption typically observed in rats after an imposed abstinence period." | 1.30 | Chronic acamprosate eliminates the alcohol deprivation effect while having limited effects on baseline responding for ethanol in rats. ( Durbin, P; Heyser, CJ; Koob, GF; Schulteis, G, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (2.97) | 18.7374 |
| 1990's | 9 (8.91) | 18.2507 |
| 2000's | 40 (39.60) | 29.6817 |
| 2010's | 43 (42.57) | 24.3611 |
| 2020's | 6 (5.94) | 2.80 |
| Authors | Studies |
|---|---|
| Ho, MF | 1 |
| Zhang, C | 1 |
| Wei, L | 1 |
| Zhang, L | 1 |
| Moon, I | 1 |
| Geske, JR | 1 |
| Skime, MK | 1 |
| Choi, DS | 3 |
| Biernacka, JM | 1 |
| Oesterle, TS | 1 |
| Frye, MA | 1 |
| Seppala, MD | 1 |
| Karpyak, VM | 2 |
| Li, H | 1 |
| Weinshilboum, RM | 2 |
| Costa-Valle, MT | 1 |
| Gomes, JF | 1 |
| De Oliveira, CR | 1 |
| Scherer, A | 1 |
| Franco De Oliveira, SCWSE | 1 |
| Menezes, RCR | 1 |
| Leal, MB | 1 |
| Romão, PRT | 1 |
| Dallegrave, E | 1 |
| Ulenius, L | 2 |
| Adermark, L | 2 |
| Söderpalm, B | 6 |
| Ericson, M | 6 |
| Pulcinelli, RR | 1 |
| de Paula, LF | 1 |
| Nietiedt, NA | 1 |
| Bandiera, S | 1 |
| Hansen, AW | 1 |
| Izolan, LDR | 1 |
| Almeida, RF | 1 |
| Gomez, R | 1 |
| Tarragon, E | 1 |
| Calleja-Conde, J | 1 |
| Giné, E | 2 |
| Segovia-Rodríguez, L | 1 |
| Durán-González, P | 1 |
| Echeverry-Alzate, V | 2 |
| Hofmann, V | 1 |
| Sundermann, TR | 1 |
| Schmitt, G | 1 |
| Bartel, M | 1 |
| Lidö, HH | 2 |
| Luginbühl, M | 2 |
| König, S | 2 |
| Schürch, S | 1 |
| Weinmann, W | 2 |
| de Dios, I | 1 |
| Rialp, G | 1 |
| Franco, S | 1 |
| Romero, M | 1 |
| Ortega, M | 1 |
| Nieto, Y | 1 |
| Andrén, A | 1 |
| Jonsson, S | 1 |
| DeSantis, SM | 3 |
| Bandyopadhyay, D | 2 |
| Baker, NL | 1 |
| Randall, PK | 1 |
| Anton, RF | 2 |
| Prisciandaro, JJ | 3 |
| O'Malley, SS | 9 |
| O'Connor, PG | 3 |
| Oka, M | 1 |
| Hirouchi, M | 1 |
| Tamura, M | 1 |
| Sugahara, S | 1 |
| Oyama, T | 1 |
| Liang, J | 1 |
| Olsen, RW | 1 |
| Stout, RL | 1 |
| Braciszewski, JM | 1 |
| Subbaraman, MS | 1 |
| Kranzler, HR | 1 |
| Falk, D | 2 |
| Gueorguieva, R | 3 |
| Wu, R | 3 |
| Weisner, C | 1 |
| Fucito, LM | 1 |
| Hoffmann, S | 1 |
| Mann, K | 5 |
| Hulin, MW | 1 |
| Lawrence, MN | 1 |
| Amato, RJ | 1 |
| Weed, PF | 1 |
| Winsauer, PJ | 1 |
| Soyka, M | 4 |
| Lieb, M | 1 |
| Patel, SN | 1 |
| Parikh, M | 1 |
| Lau-Cam, CA | 1 |
| Hu, W | 1 |
| Morris, B | 1 |
| Carrasco, A | 1 |
| Kroener, S | 1 |
| Witkiewitz, K | 3 |
| Vowles, KE | 1 |
| McCallion, E | 1 |
| Frohe, T | 1 |
| Kirouac, M | 1 |
| Maisto, SA | 1 |
| Shimizu, C | 1 |
| Oki, Y | 1 |
| Mitani, Y | 1 |
| Nakamura, T | 1 |
| Nabeshima, T | 1 |
| McHugh, RK | 1 |
| Fitzmaurice, GM | 1 |
| Griffin, ML | 1 |
| Weiss, RD | 1 |
| Ho, AM | 1 |
| Qiu, Y | 1 |
| Jia, YF | 1 |
| Aguiar, FS | 1 |
| Hinton, DJ | 2 |
| Roos, CR | 1 |
| Rutjens, S | 1 |
| Furrer, J | 1 |
| Kiefer, F | 3 |
| Spanagel, R | 6 |
| Littleton, J | 1 |
| Yang, HT | 1 |
| Chien, YW | 1 |
| Tsen, JH | 1 |
| Chang, CC | 1 |
| Chang, JH | 1 |
| Huang, SY | 1 |
| Simms, JA | 1 |
| Steensland, P | 1 |
| Medina, B | 1 |
| Abernathy, KE | 1 |
| Chandler, LJ | 1 |
| Wise, R | 1 |
| Bartlett, SE | 1 |
| Gupta, T | 1 |
| Syed, YM | 1 |
| Revis, AA | 1 |
| Miller, SA | 1 |
| Martinez, M | 1 |
| Cohn, KA | 1 |
| Demeyer, MR | 1 |
| Patel, KY | 1 |
| Brzezinska, WJ | 1 |
| Rhodes, JS | 1 |
| Grósz, A | 1 |
| Szatmári, A | 1 |
| Garbutt, JC | 1 |
| Czachowski, CL | 2 |
| Delory, MJ | 1 |
| Park, T | 1 |
| Cho, K | 1 |
| Park, SH | 1 |
| Lee, DH | 1 |
| Kim, HW | 1 |
| Leggio, L | 1 |
| Ray, LA | 2 |
| Kenna, GA | 2 |
| Swift, RM | 3 |
| Hammarberg, A | 1 |
| Nylander, I | 1 |
| Zhou, Q | 1 |
| Jayaram-Lindström, N | 1 |
| Reid, MS | 1 |
| Franck, J | 1 |
| Chau, P | 2 |
| Höifödt-Lidö, H | 1 |
| Löf, E | 1 |
| Donovan, D | 2 |
| Rounsaville, BJ | 2 |
| Couper, D | 2 |
| Krystal, JH | 2 |
| Vengeliene, V | 2 |
| Leonardi-Essmann, F | 1 |
| Sommer, WH | 1 |
| Marston, HM | 1 |
| Wang, XQ | 1 |
| Liu, L | 1 |
| Fertig, J | 1 |
| Mattson, M | 1 |
| Ryan, M | 1 |
| Johnson, B | 1 |
| Stout, R | 1 |
| Litten, RZ | 1 |
| Longabaugh, R | 1 |
| Wirtz, PW | 1 |
| Zywiak, WH | 1 |
| Capone, C | 1 |
| Kahler, CW | 1 |
| Lee, MR | 1 |
| Wu, J | 1 |
| Mishra, PK | 1 |
| Port, JD | 1 |
| Macura, SI | 1 |
| Bowen, S | 1 |
| Donovan, DM | 1 |
| Specka, M | 1 |
| Lieb, B | 1 |
| Kuhlmann, T | 1 |
| Frommann, N | 1 |
| Wobrock, T | 1 |
| Schifano, F | 1 |
| Gaebel, W | 1 |
| Scherbaum, N | 1 |
| Brager, A | 1 |
| Prosser, RA | 2 |
| Glass, JD | 2 |
| Ralevski, E | 1 |
| O'Brien, E | 1 |
| Jane, JS | 1 |
| Dean, E | 1 |
| Dwan, R | 1 |
| Petrakis, I | 1 |
| Brager, AJ | 1 |
| Chiuzan, C | 1 |
| Brown, DG | 1 |
| Brady, KT | 1 |
| Tolliver, BK | 1 |
| Marston, H | 1 |
| Shi, X | 1 |
| Yao, D | 1 |
| Chen, C | 1 |
| Preuss, UW | 1 |
| Tuda-Arízcun, M | 1 |
| Bühler, KM | 1 |
| Santos, Á | 1 |
| Olmos, P | 1 |
| Gorriti, MÁ | 1 |
| Huertas, E | 1 |
| Rodríguez de Fonseca, F | 1 |
| López-Moreno, JA | 1 |
| Bujarski, S | 1 |
| Lunny, K | 1 |
| You, JS | 1 |
| Kim, SY | 1 |
| Park, SY | 1 |
| Chang, KJ | 1 |
| Heyser, CJ | 2 |
| Moc, K | 1 |
| Koob, GF | 3 |
| Kim, SG | 1 |
| Han, BD | 1 |
| Park, JM | 1 |
| Kim, MJ | 1 |
| Stromberg, MF | 2 |
| Chick, J | 1 |
| Lehert, P | 3 |
| Landron, F | 1 |
| Brasser, SM | 1 |
| McCaul, ME | 1 |
| Houtsmuller, EJ | 1 |
| Verheul, R | 1 |
| Geerlings, PJ | 1 |
| Koeter, MW | 1 |
| van den Brink, W | 1 |
| O'Brien, CP | 2 |
| Lee, TH | 1 |
| McGeary, JE | 1 |
| Pendyala, G | 1 |
| Abarca, C | 1 |
| Zghoul, T | 1 |
| Sanchis-Segura, C | 1 |
| Magnone, MC | 1 |
| Lascorz, J | 1 |
| Depner, M | 1 |
| Holzberg, D | 1 |
| Schreiber, S | 1 |
| Matsuda, F | 1 |
| Lathrop, M | 1 |
| Schumann, G | 1 |
| Albrecht, U | 1 |
| Bachteler, D | 1 |
| Economidou, D | 1 |
| Danysz, W | 1 |
| Ciccocioppo, R | 1 |
| Piorunska-Mikolajczak, A | 1 |
| Piorunska-Stolzmann, M | 1 |
| Mikolajczak, P | 1 |
| Okulicz-Kozaryn, I | 1 |
| Kaminska, E | 1 |
| Sarria, AJ | 1 |
| Surra, JC | 1 |
| Acin, S | 1 |
| Carnicer, R | 1 |
| Navarro, MA | 1 |
| Arbones-Mainar, JM | 1 |
| Guillen, N | 1 |
| Martinez-Gracia, MV | 1 |
| Arnal, C | 1 |
| Osada, J | 1 |
| Escher, T | 1 |
| Mittleman, G | 1 |
| Jahn, H | 1 |
| Otte, C | 1 |
| Nakovics, H | 1 |
| Wiedemann, K | 1 |
| Batel, P | 1 |
| Balester-Mouret, S | 1 |
| Füllgrabe, MW | 1 |
| Heidbreder, CA | 1 |
| Andreoli, M | 1 |
| Marcon, C | 1 |
| Hutcheson, DM | 1 |
| Gardner, EL | 1 |
| Ashby, CR | 1 |
| Oteri, A | 1 |
| Salvo, F | 1 |
| Caputi, AP | 1 |
| Calapai, G | 1 |
| Rösner, S | 1 |
| Leucht, S | 1 |
| Blednov, YA | 1 |
| Harris, RA | 1 |
| Boismare, F | 3 |
| Daoust, M | 4 |
| Moore, N | 3 |
| Saligaut, C | 2 |
| Lhuintre, JP | 3 |
| Chretien, P | 1 |
| Durlach, J | 1 |
| Ades, J | 1 |
| Lejoyeux, M | 1 |
| Sass, H | 1 |
| Zieglgänsberger, W | 2 |
| Hölter, SM | 1 |
| Allingham, K | 1 |
| Landgraf, R | 1 |
| Riesselmann, B | 1 |
| Rosenbaum, F | 1 |
| Schneider, V | 1 |
| Schulteis, G | 1 |
| Durbin, P | 2 |
| Farren, CK | 1 |
| Fiellin, DA | 1 |
| Reid, MC | 1 |
| Quertemont, E | 1 |
| Lallemand, F | 1 |
| Colombo, G | 1 |
| De Witte, P | 2 |
| Liu, XQ | 1 |
| Li, YH | 1 |
| Legg, BH | 1 |
| Samson, HH | 1 |
| Mackler, SA | 1 |
| Volpicelli, JR | 1 |
| Chester, JA | 1 |
| Grahame, NJ | 1 |
| Li, TK | 1 |
| Lumeng, L | 1 |
| Froehlich, JC | 1 |
| Olive, MF | 1 |
| Nannini, MA | 1 |
| Ou, CJ | 1 |
| Koenig, HN | 1 |
| Hodge, CW | 1 |
| Ernouf, D | 1 |
| Poulain, D | 1 |
| Narcisse, G | 1 |
| Gewiss, M | 1 |
| Heidbreder, C | 1 |
| Opsomer, L | 1 |
| Tran, G | 1 |
| Steru, L | 1 |
| Langrenon, S | 1 |
| Parot, P | 1 |
| Ladure, P | 1 |
| Libert, C | 1 |
| Flipo, JL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pilot Study of Combined Treatment for Veterans With Chronic Pain & Opiate Misuse[NCT02423772] | 37 participants (Actual) | Interventional | 2014-08-31 | Completed | |||
| Imaging Framework for Testing GABAergic/Glutamatergic Drugs in Bipolar Alcoholics[NCT03220776] | Phase 2 | 54 participants (Actual) | Interventional | 2017-08-07 | Completed | ||
| Campral (Acamprosate) Treatment of Alcohol Dependence in a Family Medicine Setting: A Randomized, Double-Blind Placebo-Controlled Study[NCT00381043] | Phase 4 | 100 participants (Actual) | Interventional | 2006-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Concentrations of GABA+, referenced to unsuppressed water and corrected for within-voxel CSF proportion, in dorsal anterior cingulate cortex measured via Proton Magnetic Resonance Spectroscopy (i.e., MEGA-PRESS). (NCT03220776)
Timeframe: Day 5 of each experimental condition
| Intervention | mmol/kg (Mean) |
|---|---|
| N-Acetylcysteine | 3.90 |
| Gabapentin | 3.93 |
| Placebo Oral Tablet | 3.73 |
Concentrations of Glx (i.e., glutamate + glutamine), referenced to unsuppressed water and corrected for within-voxel CSF proportion, in dorsal anterior cingulate cortex measured via Proton Magnetic Resonance Spectroscopy. (NCT03220776)
Timeframe: Day 5 of each experimental condition
| Intervention | mmol/kg (Mean) |
|---|---|
| N-Acetylcysteine | 21.59 |
| Gabapentin | 21.69 |
| Placebo Oral Tablet | 22.25 |
% of individuals with evidence for 80% compliance with medication based on returned blister packs and weekly diaries. (NCT00381043)
Timeframe: 12 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| 1- Acamprosate | 93.3 |
| 2 - Sugar Pill - Placebo | 91.6 |
Percentage of participants who dropped out of study by drug condition (NCT00381043)
Timeframe: 12 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| 1- Acamprosate | 21.5 |
| 2 - Sugar Pill - Placebo | 16.3 |
% of Heavy drinking days (5 or more drinks/d for a man or 4 or more drinks/d for a woman) over the 12 weeks of the trial. (NCT00381043)
Timeframe: 12 weeks
| Intervention | percentage of heavy drinking days (Mean) |
|---|---|
| 1- Acamprosate | 15.8 |
| 2 - Sugar Pill - Placebo | 18.4 |
Range of overall severity of illness: 1, normal, not at all ill; 2, borderline ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, extremely ill (NCT00381043)
Timeframe: 12 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| 1- Acamprosate | 2.3 |
| 2 - Sugar Pill - Placebo | 2.4 |
%Days without any alcohol consumption over the treatment period (NCT00381043)
Timeframe: 12 weeks
| Intervention | percentage of days (Mean) |
|---|---|
| 1- Acamprosate | 40.7 |
| 2 - Sugar Pill - Placebo | 41.6 |
% of subjects with no drinking during the 12 week treatment trial (NCT00381043)
Timeframe: 12 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| 1- Acamprosate | 5.9 |
| 2 - Sugar Pill - Placebo | 19.1 |
Number of individuals retained in the trial by acamprosate vs placebo group (NCT00381043)
Timeframe: 12 weeks
| Intervention | participants (Number) |
|---|---|
| 1- Acamprosate | 39 |
| 2 - Sugar Pill - Placebo | 41 |
16 reviews available for taurine and Alcohol Drinking
| Article | Year |
|---|---|
Alcohol mixed with energy drinks: what about taurine?
Topics: Alcohol Drinking; Animals; Caffeine; Carbonated Beverages; Drug Interactions; Energy Drinks; Ethanol | 2021 |
The Glycine Receptor-A Functionally Important Primary Brain Target of Ethanol.
Topics: Acamprosate; Alcohol Drinking; Animals; Brain; Dopamine; Ethanol; Humans; Naltrexone; Receptors, Gly | 2017 |
Medications for unhealthy alcohol use: across the spectrum.
Topics: Acamprosate; Alcohol Drinking; Alcoholism; Animals; Disulfiram; Dopamine Agents; Fructose; Humans; N | 2011 |
Alcohol use disorders and current pharmacological therapies: the role of GABA(A) receptors.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Animals; Benzodiazepines; Disulfiram; | 2014 |
Recent Developments in Pharmacotherapy of Alcoholism.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Anticonvulsants; Baclofen; Humans; Na | 2015 |
Acamprosate: recent findings and future research directions.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Animals; gamma-Aminobutyric Acid; Glu | 2008 |
[The history, ingredients and effects of energy drinks].
Topics: Alcohol Drinking; Austria; Beverages; Caffeine; Carnitine; Central Nervous System Stimulants; Coffee | 2008 |
The state of pharmacotherapy for the treatment of alcohol dependence.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Baclofen; Delayed-Action Preparations | 2009 |
Acamprosate: how, where, and for whom does it work? Mechanism of action, treatment targets, and individualized therapy.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Animals; Drug Delivery Systems; Human | 2010 |
Predictors of acamprosate efficacy: results from a pooled analysis of seven European trials including 1485 alcohol-dependent patients.
Topics: Acamprosate; Adult; Age Factors; Aged; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Anxiety; Do | 2005 |
Pharmacotherapy, pharmacogenomics, and the future of alcohol dependence treatment, part 1.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcohol-Related Disorders; Animals; Clinical Tria | 2004 |
Understanding the role of dietary components on atherosclerosis using genetic engineered mouse models.
Topics: Alcohol Drinking; Allergy and Immunology; Animals; Antioxidants; Apolipoproteins E; Arginine; Arteri | 2006 |
Acamprosate supports abstinence, naltrexone prevents excessive drinking: evidence from a meta-analysis with unreported outcomes.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Humans; Middle Aged; Naltrexon | 2008 |
Clinical evaluation of acamprosate to reduce alcohol intake.
Topics: Acamprosate; Alcohol Drinking; Alcoholism; Controlled Clinical Trials as Topic; Double-Blind Method; | 1993 |
New therapies for alcohol problems: application to primary care.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcohol-Related Disorders; Clinical Trials as Top | 2000 |
Animal models of craving for ethanol.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Animals; Behavior, Addictive; Conditioning, Opera | 2000 |
18 trials available for taurine and Alcohol Drinking
| Article | Year |
|---|---|
Modeling longitudinal drinking data in clinical trials: an application to the COMBINE study.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Cognitive Behavioral Therapy; | 2013 |
What happens when people discontinue taking medications? Lessons from COMBINE.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Behavior Therapy; Combined Mod | 2014 |
Pain as a predictor of heavy drinking and any drinking lapses in the COMBINE study and the UK Alcohol Treatment Trial.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcohol Drinking; Alcohol-Related Disorders; Behavior Therap | 2015 |
Reward and relief dimensions of temptation to drink: construct validity and role in predicting differential benefit from acamprosate and naltrexone.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Female; Humans; Male; Naltrexo | 2017 |
Blood glucose level, alcohol heavy drinking, and alcohol craving during treatment for alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) Study.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Behavior Therapy; Blood Glucos | 2009 |
The effect of acamprosate on alcohol craving and correlation with hypothalamic pituitary adrenal (HPA) axis hormones and beta-endorphin.
Topics: Acamprosate; Adrenocorticotropic Hormone; Alcohol Deterrents; Alcohol Drinking; Alcohol-Related Diso | 2009 |
Network support as a prognostic indicator of drinking outcomes: the COMBINE Study.
Topics: Acamprosate; Adult; Alcohol Drinking; Alcoholism; Female; Humans; Male; Naltrexone; Prognosis; Socia | 2010 |
Does family history of alcoholism moderate naltrexone's effects on alcohol use?
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Behavior Therapy; Family; Fema | 2011 |
Moderating effects of a craving intervention on the relation between negative mood and heavy drinking following treatment for alcohol dependence.
Topics: Acamprosate; Adult; Affect; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Behavior Therapy; Comb | 2011 |
Marked reduction of heavy drinking did not reduce nicotine use over 1 year in a clinical sample of alcohol-dependent patients.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Cognitive Behavioral Therapy; Ethanol | 2011 |
Effects of acamprosate on cognition in a treatment study of patients with schizophrenia spectrum disorders and comorbid alcohol dependence.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Cognition; Double-Blind Method; Femal | 2011 |
Baseline trajectories of heavy drinking and their effects on postrandomization drinking in the COMBINE Study: empirically derived predictors of drinking outcomes during treatment.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Behavior Therapy; Combined Mod | 2012 |
Impact of depressive symptoms on future alcohol use in patients with co-occurring bipolar disorder and alcohol dependence: a prospective analysis in an 8-week randomized controlled trial of acamprosate.
Topics: Acamprosate; Adolescent; Adult; Aged; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Behavior, Ad | 2012 |
Simultaneous modeling of the impact of treatments on alcohol consumption and quality of life in the COMBINE study: a coupled hidden Markov analysis.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Behavior Therapy; Combined Modality T | 2012 |
The effects of drinking goal on treatment outcome for alcoholism.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Cognitive Behavioral Therapy; | 2013 |
Alcohol effects during acamprosate treatment: a dose-response study in humans.
Topics: Acamprosate; Adult; Alcohol Drinking; Alcoholic Intoxication; Analysis of Variance; Dose-Response Re | 2004 |
Relapse prevention by acamprosate. Results from a placebo-controlled study on alcohol dependence.
Topics: Acamprosate; Adult; Aged; Alcohol Drinking; Alcoholism; Double-Blind Method; Female; Follow-Up Studi | 1996 |
Acamprosate appears to decrease alcohol intake in weaned alcoholics.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcohol Drinking; Alcohol Withdrawal Delirium; Alcoholism; D | 1990 |
67 other studies available for taurine and Alcohol Drinking
| Article | Year |
|---|---|
Genetic variants associated with acamprosate treatment response in alcohol use disorder patients: A multiple omics study.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Ethanol; Genome-Wide Association Stud | 2022 |
Energy drinks and alcohol in a binge drinking protocol in Wistar rats: Male and female behavioral and reproductive effects.
Topics: Alcohol Drinking; Animals; Binge Drinking; Caffeine; Energy Drinks; Ethanol; Female; Male; Rats; Rat | 2022 |
Energy drink constituents (caffeine and taurine) selectively potentiate ethanol-induced locomotion in mice.
Topics: Alcohol Drinking; Alcoholism; Animals; Caffeine; Dopamine; Energy Drinks; Ethanol; Locomotion; Male; | 2019 |
Taurine enhances voluntary alcohol intake and promotes anxiolytic-like behaviors in rats.
Topics: Alcohol Drinking; Animals; Anti-Anxiety Agents; Ethanol; Male; Rats; Rats, Wistar; Taurine | 2020 |
Development and validation of an analytical method for the simultaneous determination of the alcohol biomarkers ethyl glucuronide, ethyl sulfate, N-acetyltaurine, and 16:0/18:1-phosphatidylethanol in human blood.
Topics: Alcohol Drinking; Biomarkers; Chromatography, High Pressure Liquid; Ethanol; Glucuronates; Glyceroph | 2022 |
Evaluation of N-acetyltaurine as an ethanol marker in human blood.
Topics: Adult; Alcohol Drinking; Biomarkers; Blood Alcohol Content; Chromatography, Liquid; Ethanol; Female; | 2017 |
The role of chronic nutritional supplements consumption in a fulminant serotonin syndrome due to citalopram intoxication.
Topics: Adult; Alcohol Drinking; Antidepressive Agents, Second-Generation; Citalopram; Depression; Dietary S | 2019 |
Different dopamine tone in ethanol high- and low-consuming Wistar rats.
Topics: Alcohol Drinking; Animals; Behavior, Animal; Central Nervous System Depressants; Cerebrospinal Fluid | 2020 |
Acamprosate {monocalcium bis(3-acetamidopropane-1-sulfonate)} reduces ethanol-drinking behavior in rats and glutamate-induced toxicity in ethanol-exposed primary rat cortical neuronal cultures.
Topics: 6-Cyano-7-nitroquinoxaline-2,3-dione; Acamprosate; Alcohol Drinking; Animals; Behavior, Animal; Cell | 2013 |
Predictors of abstinence from heavy drinking during treatment in COMBINE and external validation in PREDICT.
Topics: Acamprosate; Age Factors; Alcohol Abstinence; Alcohol Deterrents; Alcohol Drinking; Behavior Therapy | 2014 |
Comparison of dehydroepiandrosterone (DHEA) and pregnanolone with existing pharmacotherapies for alcohol abuse on ethanol- and food-maintained responding in male rats.
Topics: Acamprosate; Alcohol Drinking; Alcoholism; Animals; Dehydroepiandrosterone; Dose-Response Relationsh | 2015 |
Impact of light ethanol intake and of taurine, separately and together, on pathways of glucose metabolism in the kidney of diabetic rats.
Topics: Alcohol Drinking; Animals; Blood Glucose; Carbohydrate Metabolism; Diabetes Mellitus, Experimental; | 2015 |
Effects of acamprosate on attentional set-shifting and cellular function in the prefrontal cortex of chronic alcohol-exposed mice.
Topics: Acamprosate; Action Potentials; Alcohol Drinking; Alcoholism; Animals; Attention; Ethanol; Membrane | 2015 |
Factors Affecting Ethanol-Induced Conditioned Place Preference and Locomotor Sensitization in Mice.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Animals; Association Learning; Condit | 2015 |
Association between a brief alcohol craving measure and drinking in the following week.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Cognitive Behavioral Therapy; | 2016 |
Combined Effects of Acamprosate and Escitalopram on Ethanol Consumption in Mice.
Topics: Acamprosate; Alcohol Drinking; Animals; Anxiety; Citalopram; Depression; Drug Therapy, Combination; | 2016 |
N-Acetyltaurine as a novel urinary ethanol marker in a drinking study.
Topics: Adult; Alcohol Drinking; Biomarkers; Blood Alcohol Content; Chromatography, Liquid; Ethanol; Female; | 2016 |
Taurine supplementation improves the utilization of sulfur-containing amino acids in rats continually administrated alcohol.
Topics: Alcohol Drinking; Animals; Cysteine; Ethanol; Methionine; Pyridoxal Phosphate; Rats; Rats, Sprague-D | 2009 |
Intermittent access to 20% ethanol induces high ethanol consumption in Long-Evans and Wistar rats.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Animals; Ethanol; Male; Models, Animal; Naltrexon | 2008 |
Acute effects of acamprosate and MPEP on ethanol Drinking-in-the-Dark in male C57BL/6J mice.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Animals; Darkness; Disease Models, An | 2008 |
Acamprosate and naltrexone treatment effects on ethanol and sucrose seeking and intake in ethanol-dependent and nondependent rats.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Animals; Body Weight; Conditioning, O | 2009 |
Taurine normalizes blood levels and urinary loss of selenium, chromium, and manganese in rats chronically consuming alcohol.
Topics: Alcohol Drinking; Animals; Chromium; Ethanol; Homeostasis; Manganese; Rats; Selenium; Taurine; Weigh | 2009 |
Glycine receptors in the nucleus accumbens involved in the ethanol intake-reducing effect of acamprosate.
Topics: Acamprosate; Alcohol Drinking; Animals; Dopamine; Ethanol; Male; Microinjections; Nucleus Accumbens; | 2010 |
Alcohol dependence: after the withdrawal phase. Long-term abstinence: better health and psychosocial status. Psychosocial support for a chronic disorder. Some drugs are useful adjuncts to medical support.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcohol-Related Disorders; Alcoholics; Alcoholism | 2009 |
Naltrexone and combined behavioral intervention effects on trajectories of drinking in the COMBINE study.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcohol Drinking; Behavior Therapy; Combined Modality Therap | 2010 |
Glycine transporter-1 blockade leads to persistently reduced relapse-like alcohol drinking in rats.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Animals; Corpus Striatum; Disease Mod | 2010 |
Percentage of subjects with no heavy drinking days: evaluation as an efficacy endpoint for alcohol clinical trials.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Female; Fructose; Humans; Male; Naltr | 2010 |
Acamprosate reduces ethanol drinking behaviors and alters the metabolite profile in mice lacking ENT1.
Topics: Acamprosate; Alcohol Drinking; Animals; Equilibrative Nucleoside Transporter 1; Ethanol; Glutamic Ac | 2011 |
Acamprosate-responsive brain sites for suppression of ethanol intake and preference.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Animals; Brain; Circadian Rhythm; Drinking; Food | 2011 |
The mGluR5 antagonist MPEP elevates accumbal dopamine and glycine levels; interaction with strychnine-sensitive glycine receptors.
Topics: Alcohol Drinking; Animals; beta-Alanine; Dopamine; Dose-Response Relationship, Drug; Excitatory Amin | 2011 |
Circadian and acamprosate modulation of elevated ethanol drinking in mPer2 clock gene mutant mice.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Animals; Circadian Rhythm; Ethanol; Gene Expressi | 2011 |
The glycine reuptake inhibitor Org24598 and acamprosate reduce ethanol intake in the rat; tolerance development to acamprosate but not to Org24598.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Animals; beta-Alanine; Dopamine; Drug Tolerance; | 2012 |
Identification of N-acetyltaurine as a novel metabolite of ethanol through metabolomics-guided biochemical analysis.
Topics: Acetates; Alcohol Drinking; Animals; Biomarkers; Central Nervous System Depressants; Cytochrome P-45 | 2012 |
Commentary on the study: impact of depressive symptoms on future alcohol use in patients with co-occurring bipolar disorder and alcohol dependence: a prospective analysis in an 8-week randomized controlled trial of acamprosate (Prisciandaro et al.).
Topics: Alcohol Drinking; Alcoholism; Behavior, Addictive; Bipolar Disorder; Depression; Female; Humans; Mal | 2012 |
Cocaine reverses the naltrexone-induced reduction in operant ethanol self-administration: the effects on immediate-early gene expression in the rat prefrontal cortex.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Animals; Carrier Proteins; Cocaine; Conditioning, | 2012 |
Dietary taurine and nutrient intake and dietary quality by alcohol consumption level in Korean male college students.
Topics: Alcohol Drinking; Body Composition; Diet; Food; Humans; Male; Nutritional Status; Republic of Korea; | 2013 |
[Deficits in preventing recurrence in alcoholic patients. Withdrawal--and immediately back to the bottle].
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Animals; Clinical Trials as Topic; Co | 2003 |
Effects of naltrexone alone and in combination with acamprosate on the alcohol deprivation effect in rats.
Topics: Acamprosate; Alcohol Drinking; Animals; Behavior, Addictive; Conditioning, Operant; Dose-Response Re | 2003 |
Effect of the combination of naltrexone and acamprosate on alcohol intake in mice.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Animals; Dose-Response Relationship, | 2004 |
Does acamprosate improve reduction of drinking as well as aiding abstinence?
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Clinical Trials as Topic; Humans; Sec | 2003 |
The mosaic of addiction.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Behavior, Addictive; Disease Models, | 2004 |
Ask the doctor. I need to quit drinking, but don't think I can do it on my own. Can I use a drug like Antabuse even though I have heart disease?
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Contraindications; Disulfiram; Heart Diseases; Hu | 2004 |
The clock gene Per2 influences the glutamatergic system and modulates alcohol consumption.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Amino Acid Transport System X-AG; Ani | 2005 |
The effects of acamprosate and neramexane on cue-induced reinstatement of ethanol-seeking behavior in rat.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Animals; Conditioning, Operant; Cues; Cyclopentan | 2005 |
Acamprosate involvement in triacylglycerol hydrolysis and transacylation with cholesterol in chronically ethanol-drinking rats.
Topics: Acamprosate; Acylation; Alcohol Deterrents; Alcohol Drinking; Animals; Cholesterol; Ethanol; Hydroly | 2004 |
Schedule-induced alcohol drinking: non-selective effects of acamprosate and naltrexone.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Animals; Appetitive Behavior; Dose-Re | 2006 |
Effects of treatment with acamprosate on beta-endorphin plasma concentration in humans with high alcohol preference.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Animals; beta-Endorphin; Bioma | 2006 |
[Maintaining abstinence after alcohol detoxification].
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Ambulatory Care; Behavior Therapy; Cl | 2006 |
Influence of age at drinking onset on the alcohol deprivation effect and stress-induced drinking in female rats.
Topics: Acamprosate; Age of Onset; Aging; Alcohol Deterrents; Alcohol Drinking; Animals; Central Nervous Sys | 2007 |
Evidence for the role of dopamine D3 receptors in oral operant alcohol self-administration and reinstatement of alcohol-seeking behavior in mice.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Animals; Conditioning, Operant; Dose- | 2007 |
Intake of energy drinks in association with alcoholic beverages in a cohort of students of the School of Medicine of the University of Messina.
Topics: Adult; Alcohol Drinking; Alcoholic Beverages; Beverages; Caffeine; Central Nervous System Depressant | 2007 |
Metabotropic glutamate receptor 5 (mGluR5) regulation of ethanol sedation, dependence and consumption: relationship to acamprosate actions.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Analysis of Variance; Animals; Behavi | 2008 |
A homotaurine derivative reduces the voluntary intake of ethanol by rats: are cerebral GABA receptors involved?
Topics: Acamprosate; Alcohol Drinking; Animals; Anticonvulsants; Brain; Calcium Chloride; Male; Rats; Recept | 1984 |
Glutamine-induced alterations in the content of brain amino acid neurotransmitters in rats with different alcohol motivation.
Topics: Alcohol Drinking; Amino Acids; Animals; Brain; gamma-Aminobutyric Acid; Glutamates; Glutamic Acid; G | 1984 |
Acamprosate and alcohol: I. Effects on alcohol intake following alcohol deprivation in the rat.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Animals; Dose-Response Relationship, Drug; Ethano | 1996 |
[Alcohol and energy drink--can combined consumption of both beverages modify automobile driving fitness?].
Topics: Accidents, Traffic; Adult; Alcohol Drinking; Alcoholic Intoxication; Beverages; Caffeine; Dose-Respo | 1996 |
Chronic acamprosate eliminates the alcohol deprivation effect while having limited effects on baseline responding for ethanol in rats.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Animals; Central Nervous System Depressants; Cond | 1998 |
Occurrence and management of depression in the context of naltrexone treatment of alcoholism.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Comorbidity; Depressive Disorder; Dia | 1999 |
Taurine and ethanol preference: a microdialysis study using Sardinian alcohol-preferring and non-preferring rats.
Topics: Alanine; Alcohol Drinking; Animals; Arginine; Chromatography, High Pressure Liquid; Conditioning, Ps | 2000 |
Epidemiological and nutritional research on prevention of cardiovascular disease in China.
Topics: Adult; Alcohol Drinking; Blood Pressure; Body Constitution; Cardiovascular Diseases; China; Choleste | 2000 |
Effects of acamprosate on ethanol-seeking and self-administration in the rat.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Animals; Male; Rats; Rats, Long-Evans; Reinforcem | 2001 |
Effect of acamprosate and naltrexone, alone or in combination, on ethanol consumption.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Animals; Male; Naltrexone; Narcotic Antagonists; | 2001 |
Effects of acamprosate on sensitization to the locomotor-stimulant effects of alcohol in mice selectively bred for high and low alcohol preference.
Topics: Acamprosate; Alcohol Drinking; Animals; Drug Interactions; Ethanol; Female; Genotype; Male; Mice; Mi | 2001 |
Effects of acute acamprosate and homotaurine on ethanol intake and ethanol-stimulated mesolimbic dopamine release.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Animals; Central Nervous System Depressants; Dopa | 2002 |
Triptosine, an L-5-hydroxytryptophan derivative, reduces alcohol consumption in alcohol-preferring rats.
Topics: 5-Hydroxytryptophan; Acamprosate; Alcohol Deterrents; Alcohol Drinking; Animals; Appetite; Brain; Do | 1992 |
Acamprosate and diazepam differentially modulate alcohol-induced behavioural and cortical alterations in rats following chronic inhalation of ethanol vapour.
Topics: Acamprosate; Administration, Inhalation; Alcohol Drinking; Alcoholic Intoxication; Alcoholism; Anima | 1991 |
Noradrenaline and GABA brain receptors are co-involved in the voluntary intake of ethanol by rats.
Topics: Acamprosate; Alcohol Drinking; Animals; Bicuculline; Brain; Dibenzazepines; Male; Rats; Receptors, A | 1987 |